David Sefrioui

1.9k total citations
44 papers, 713 citations indexed

About

David Sefrioui is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, David Sefrioui has authored 44 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Cancer Research and 16 papers in Pathology and Forensic Medicine. Recurrent topics in David Sefrioui's work include Cancer Genomics and Diagnostics (21 papers), Genetic factors in colorectal cancer (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). David Sefrioui is often cited by papers focused on Cancer Genomics and Diagnostics (21 papers), Genetic factors in colorectal cancer (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). David Sefrioui collaborates with scholars based in France, Denmark and Spain. David Sefrioui's co-authors include Pierre Michel, Nasrin Sarafan‐Vasseur, Frédéric Di Fiore, Frédéric Di Fiore, Ludivine Beaussire, Florian Clatot, Julien Taı̈eb, Aziz Zaanan, Thierry Frébourg and Valérie Taly and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

David Sefrioui

38 papers receiving 704 citations

Peers

David Sefrioui

ONCOL

PFM

PRM

Ludmila Lipská Czechia

Tommasina Biscotti Italy

Richard M. Goldberg United States

José Perea Spain

Emanuela Dell’Aquila Italy

Michaela Schneiderová Czechia

U. Graeven Germany

Pedro Luiz Serrano Usón Brazil

Enrique Sanz‐García Spain

Hideya Tashiro Japan

Ludmila Lipská Czechia

David Sefrioui

440 ×1.0

322 ×0.7

ONCOL

117 ×0.5

PFM

142 ×0.7

PRM

401 ×2.6

Citations per year, relative to David Sefrioui David Sefrioui (= 1×) peers Ludmila Lipská

Countries citing papers authored by David Sefrioui

Since Specialization

Citations

This map shows the geographic impact of David Sefrioui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sefrioui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sefrioui more than expected).

Fields of papers citing papers by David Sefrioui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sefrioui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sefrioui. The network helps show where David Sefrioui may publish in the future.

Co-authorship network of co-authors of David Sefrioui

This figure shows the co-authorship network connecting the top 25 collaborators of David Sefrioui. A scholar is included among the top collaborators of David Sefrioui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sefrioui. David Sefrioui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bouattour, Mohamed, Brice Fresneau, Anthony Turpin, et al.. (2025). Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort. Digestive and Liver Disease. 57(7). 1495–1500.

Elie, Caroline, Karine Bouhier‐Leporrier, Aurélie Parzy, et al.. (2025). ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer. British Journal of Cancer. 132(9). 814–821.

Baan, Frederieke H. van der, Romain Cohen, Thomas Aparicio, et al.. (2023). Prognostic value of Lynch syndrome, BRAF^V600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts. Cancer Medicine. 12(15). 15841–15853. 7 indexed citations

Benoist, Stéphane, Patrick Devos, Stéphanie Truant, et al.. (2022). Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. World Journal of Surgical Oncology. 20(1). 131–131. 15 indexed citations

Michel, Pierre, et al.. (2022). Colorectal cancer chemoprevention: is aspirin still in the game?. Cancer Biology & Therapy. 23(1). 446–461. 24 indexed citations

Pernot, Simon, Olivier Pellerin, Pascal Artru, et al.. (2020). Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. British Journal of Cancer. 123(4). 518–524. 19 indexed citations

Pernot, Simon, Violaine Randrian, Solène Doat, et al.. (2020). 435P Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study. Annals of Oncology. 31. S426–S426.

Sefrioui, David, Céline Savoye‐Collet, Ludivine Beaussire, et al.. (2020). 1007P cfDNA and ctDNA variations are predictive of disease progression to conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC). Annals of Oncology. 31. S698–S698. 1 indexed citations

Zaanan, Aziz, Julie Henriques, Romain Cohen, et al.. (2020). Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. JNCI Journal of the National Cancer Institute. 113(4). 496–500. 5 indexed citations

10.

Schwarz, Lilian, Gabriella Pittau, David Sefrioui, et al.. (2019). “Laparoscopic Para-Aortic Lymph Node Sampling” First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. Journal of Laparoendoscopic & Advanced Surgical Techniques. 29(7). 900–904. 4 indexed citations

11.

Samalin, Emmanuelle, Anthony Turpin, Faïza Khemissa, et al.. (2019). Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). Annals of Oncology. 30. iv21–iv21. 2 indexed citations

12.

Touchefeu, Yann, Rosine Guimbaud, Christophe Louvet, et al.. (2018). Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 22(3). 577–586. 5 indexed citations

13.

Laurent, Lucie, David Sefrioui, Aurélie Parzy, et al.. (2018). CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB. 21(5). 582–588. 15 indexed citations

14.

Garlan, Fanny, Pierre Laurent‐Puig, David Sefrioui, et al.. (2017). Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clinical Cancer Research. 23(18). 5416–5425. 165 indexed citations

15.

Beaussire, Ludivine, Anne Perdrix, David Sefrioui, et al.. (2017). Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Annals of Oncology. 28. v58–v58. 3 indexed citations

16.

Sefrioui, David, Ludivine Beaussire, Florian Clatot, et al.. (2017). Heparinase enables reliable quantification of circulating tumor DNA from heparin plasma samples by droplet digital PCR. Annals of Oncology. 28. v37–v37.

17.

Tougeron, David, Romain Cohen, David Sefrioui, et al.. (2017). A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. Annals of Oncology. 28. v180–v180. 10 indexed citations

18.

Michel, Pierre, et al.. (2017). Aspirine et cancer colorectal. Bulletin du Cancer. 105(2). 171–180. 20 indexed citations

19.

Lecleire, Stéphane, Alice Gangloff, Olivier Rigal, et al.. (2014). Impact of nutritional parameter variations during definitive chemoradiotherapy in locally advanced oesophageal cancer. Digestive and Liver Disease. 46(3). 270–275. 28 indexed citations

20.

Sarafan‐Vasseur, Nasrin, David Sefrioui, David Tougeron, et al.. (2013). Genetic variations of the A13/A14 repeat located within the EGFR3′ untranslated region have no oncogenic effect in patients with colorectal cancer. BMC Cancer. 13(1). 183–183. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact